|1.||Ferrari, Patrizia: 7 articles (11/2014 - 12/2002)|
|2.||Bianchi, Giuseppe: 6 articles (11/2014 - 12/2002)|
|3.||Ferrandi, Mara: 5 articles (11/2014 - 12/2002)|
|4.||Manunta, Paolo: 4 articles (11/2014 - 01/2005)|
|5.||Ferrari, P: 4 articles (01/2006 - 09/2000)|
|6.||Bianchi, G: 4 articles (01/2006 - 09/2000)|
|7.||Ferrandi, M: 4 articles (01/2006 - 09/2000)|
|8.||Valentini, Giovanni: 3 articles (01/2011 - 03/2006)|
|9.||Molinari, I: 3 articles (01/2006 - 04/2003)|
|10.||Torielli, L: 3 articles (01/2005 - 09/2000)|
|1.||Hypertension (High Blood Pressure)
01/01/2011 - "After 4 weeks without treatment, 435 patients with uncomplicated systolic hypertension (140-169 mm Hg) were randomized to rostafuroxin (0.05, 0.15, 0.5, 1.5 or 5.0 mg/d) or matching placebo, each treatment period lasting 5 weeks. "
11/24/2010 - "Because the mechanisms that are inhibited by rostafuroxin also underlie hypertension-related organ damage, this drug may also reduce the cardiovascular risk in these patients beyond that expected by the reduction in systolic blood pressure alone."
12/01/2002 - "The findings lead to the conclusion that PST 2238 is a new antihypertensive compound that normalizes the altered function of the renal Na-K pump associated with hypertension in rat models, but that it is devoid of diuretic activity and does not induce the diuretic-associated side effects."
01/01/2005 - "The pharmacological selectivity and safety of PST 2238 suggests that the compound may be effective for the treatment of those forms of hypertension in which renal sodium handling alterations and cardiovascular complications are associated with increased production of EO."
09/01/2000 - "The ability of PST 2238 to lower blood pressure and normalize the Na-K pump both in MHS and OS rats suggests that this compound could be useful in the treatment of those forms of essential hypertension in which renal Na-handling alterations are associated with either adducin polymorphisms and/or increased OLF levels."
11/01/2014 - "To study the effect of rostafuroxin on podocyte protein changes and proteinuria, mice carrying mutant β-adducin and ouabain hypertensive rats were orally treated with 100 μg/kg per day rostafuroxin. "
11/01/2014 - "We conclude that rostafuroxin prevented podocyte lesions and proteinuria due to mutant β-adducin and ouabain in animal models. "
11/01/2014 - "Rostafuroxin protects from podocyte injury and proteinuria induced by adducin genetic variants and ouabain."
11/01/2014 - "The main purpose of the present study was to investigate whether rostafuroxin, a novel antihypertensive agent developed as a selective inhibitor of Src-SH2 interaction with mutant adducin- and ouabain-activated Na,K-ATPase, may protect podocytes from adducin- and ouabain-induced effects, thus representing a novel pharmacologic approach for the therapy of podocytopathies and proteinuria caused by the aforementioned mechanisms. "
11/01/2014 - "Treatment of animals, or incubation of cultured podocytes with rostafuroxin, reverted mutant β-adducin- and ouabain-induced effects on nephrin protein expression and proteinuria. "
01/01/2005 - "A selective ability of PST 2238 to antagonise the ouabain-induced organ hypertrophy is also documented. "
04/01/2003 - "OS rats showed a 10% increase of left ventricle and kidney weights as compared with controls, and PST 2238 (1 micro g/kg OS) prevented both ventricle and renal hypertrophy. "
01/01/2005 - "Among them, the digitoxigenin derivate, PST 2238, has been selected for its ability to antagonize the ouabain-induced effects on blood pressure and organ hypertrophy at oral doses of microgram/kg/day in vivo. "
01/01/2005 - "PST 2238 (17beta-(3-furyl)-5beta-androstane-3beta-14beta-17alpha-triol), an antagonist of endogenous ouabain, might open new possibilities for the therapy of hypertension and congestive heart failure."
05/01/2002 - "The discovery of ouabain as a new adrenal hormone affecting Na(+) metabolism and the development of the new ouabain antagonist PST 2238 allows for new possibilities for the therapy of hypertension and congestive heart failure. "
|3.||Adenosine Triphosphatases (ATPase)
|4.||Ouabain (G Strophanthin)
|5.||Messenger RNA (mRNA)
|6.||17- (3- furyl)- 5beta- androstane- 3,14,17- triol
|7.||Valproic Acid (Valproate, Semisodium)